COVID Part 2: Masks, long COVID, boosters, mandates, treatments, and more

KEYPOINTS

• 01

  Omicron hospitalization data in early 2022 looked far milder than earlier waves.

  Recorded January 17, 2022, the panel led with a Kaiser Southern California preprint: about 52,000 documented Omicron cases, none requiring mechanical ventilation. Makary argued that with four or five community infections for every documented one, that represents roughly a quarter million infections. Omicron was then 98.3% of US cases per the CDC, up from 73% in mid-December, so older severity data no longer described the dominant variant.

• 02

  A large share of 'COVID hospitalizations' were incidental.

  Hospitals reported that many admitted patients tested positive but were there for something else—about 53% at one system and 65% at Jackson Memorial in Florida. The panel's rule of thumb was 50–60% incidental, higher in highly vaccinated regions, which matters for interpreting dashboards and for whether hospital strain reflects COVID illness.

• 03

  Population immunity, not only the variant, explains much of the mildness.

  Gandhi described the debate since South African scientists first flagged Omicron. A serology study found about 79% of South African adults had antibodies despite only around 25% vaccination; one analysis estimated vaccination alone carried a hazard ratio of 0.24 for severe outcomes. Her view: T-cell and B-cell immunity from prior infection and vaccines blunts severe disease even when antibodies wane.

• 04

  T cells and B cells give durable, broad protection.

  Gandhi cited SARS-1 survivors with strong T-cell responses 17 years later, and elderly survivors of the 1918 influenza whose B cells could still make antibodies against that strain about 90 years on. Because Omicron's mutations cluster in the spike (about 32 of roughly 50 total), immunity to the whole virus—from infection or an inactivated vaccine like Covaxin—may help against future variants.

• 05

  Myocarditis risk tracks dose and spacing.

  Moderna's dose is 100 micrograms versus Pfizer's 30, which likely explains its higher myocarditis signal and why several countries avoid it in younger men. A Canadian study found higher risk after the second dose with Moderna and with shorter dose intervals, supporting Canada's 8-week spacing. An Alabama study of 175 people over 80 found immune response about 3.5 times greater when doses were spaced three months rather than three weeks.

• 06

  Boosters matter most for the old and sick.

  Per a CDC analysis discussed, the risk of a severe outcome after even two doses was tiny across the population, with a vanishingly small chance of death,while risk concentrated in people over 75 with multiple (often four) comorbidities. The panel argued booster messaging should focus there rather than on blanket mandates.

• 07

  Public risk perception was wildly distorted.

  Attia recounted a parent who estimated his unvaccinated, healthy son in his late 30s had a 50% chance of hospitalization or death; the actual data suggested a risk on the order of 0.001. Makary showed that for 5–14-year-olds, suicide risk was about 6.5 times and homicide about 5 times that of COVID, and for 15–24-year-olds car crashes, suicide, homicide and overdoses together were roughly 9–10 times greater.

• 08

  Mask quality matters; cloth masks are largely obsolete.

  Gandhi said cloth masks may once have reduced severity (possibly via humidified air) but vaccination now does that far better. The panel favored offering high-filtration masks—N95, KN95, KF94, FFP2—to those who want protection. A National Academy of Sciences study found 20-minute transmission risk of about 10.4% with surgical masks, 4.2% with an N95 lacking a nosepiece, and 0.14% with a well-sealed N95.

• 09

  One-way masking protects the wearer, which undercuts mandates.

  Because a well-fitted N95 protects the person wearing it, the panel argued high-risk people can protect themselves without population mandates. Attia noted he wants his 87-year-old father, on chemotherapy, in an N95—an individual choice rather than a rule for everyone.

• 10

  Vaccination appears to reduce long COVID.

  Gandhi, whose institution UCSF runs a post-acute COVID study, said long-term symptoms follow many severe viral infections. Three studies, including one from Israel published that morning, suggested vaccinated people had fewer long-COVID symptoms, and mild breakthrough infections in the vaccinated rarely produced lasting symptoms.

• 11

  Early treatments were underused.

  Makary said a repurposed antidepressant, fluvoxamine, reduced mortality by 91% among compliant high-risk patients in a trial, yet official bodies said evidence was insufficient. He added that concentrated convalescent plasma reduced hospitalizations by about 50% and that many physicians knew little about either, along with the new oral antivirals.

• 12

  Polarization and tribalism hardened positions.

  The group argued mandates and moralizing hardened the unvaccinated minority (about 15% of Americans over 5), and that dismissing natural immunity backfired. Attia joked about his brother being treated as a 'filthy person' for catching COVID in early 2020. They urged humility and fact-based discussion over fear-based modeling.